Skip to main content
PLOS Digital Health logoLink to PLOS Digital Health
. 2022 Jun 27;1(6):e0000060. doi: 10.1371/journal.pdig.0000060

A pilot randomised trial of a brief virtual reality scenario in smokers unmotivated to quit: Assessing the feasibility of recruitment

Olga Perski 1,2,*, Trupti Jambharunkar 1,2, Jamie Brown 1,2, Dimitra Kale 1,2
Editor: Laura M König3
PMCID: PMC9931367  PMID: 36812542

Abstract

Individual-level interventions for smokers unmotivated to quit remain scarce and have had limited success. Little is known about the potential of virtual reality (VR) for delivering messaging to smokers unmotivated to quit. This pilot trial aimed to assess the feasibility of recruitment and acceptability of a brief, theory-informed VR scenario and estimate proximal quitting outcomes. Unmotivated smokers (recruited between February-August 2021) aged 18+ years who had access to, or were willing to receive via post, a VR headset were randomly assigned (1:1) using block randomisation to view the intervention (i.e., a hospital-based scenario with motivational stop smoking messaging) or a ‘sham’ VR scenario (i.e., a scenario about the human body without any smoking-specific messaging) with a researcher present via teleconferencing software. The primary outcome was feasibility of recruitment (i.e., achieving the target sample size of 60 participants within 3 months of recruitment). Secondary outcomes included acceptability (i.e., positive affective and cognitive attitudes), quitting self-efficacy and intention to stop smoking (i.e., clicking on a weblink with additional stop smoking information). We report point estimates and 95% confidence intervals (CIs). The study protocol was pre-registered (osf.io/95tus). A total of 60 participants were randomised within 6 months (intervention: n = 30; control: n = 30), 37 of whom were recruited within a 2-month period of active recruitment following an amendment to gift inexpensive (£7) cardboard VR headsets via post. The mean (SD) age of participants was 34.4 (12.1) years, with 46.7% identifying as female. The mean (SD) cigarettes smoked per day was 9.8 (7.2). The intervention (86.7%, 95% CI = 69.3%-96.2%) and control (93.3%, 95% CI = 77.9%-99.2%) scenarios were rated as acceptable. Quitting self-efficacy and intention to stop smoking in the intervention (13.3%, 95% CI = 3.7%-30.7%; 3.3%, 95% CI = 0.1%-17.2%) and control (26.7%, 95% CI = 12.3%-45.9%; 0%, 95% CI = 0%-11.6%) arm were comparable. The target sample size was not achieved within the feasibility window; however, an amendment to gift inexpensive headsets via post appeared feasible. The brief VR scenario appeared acceptable to smokers unmotivated to quit.

Author summary

Virtual reality (VR)–i.e., the creation of a digital environment which gives rise to strong sensory experiences–can be used to deliver motivational messaging to smokers unmotivated to stop. However, little is currently known about the feasibility of recruiting smokers with access to a VR headset into an online trial or the acceptability of a VR scenario focused on the health consequences of smoking in smokers unmotivated to stop. We helped develop a brief, theory-based VR scenario in which participants attended a consultation with a chest physician in a hospital clinic room. We randomised 60 adult smokers to view the intervention or control VR scenario. We found that although the target sample size was not achieved within 3 months from the trial start date (i.e., the pre-specified feasibility window), gifting inexpensive VR headsets to smokers via post appeared feasible. In addition, the brief VR scenario appeared acceptable to smokers unmotivated to stop. This study was–to our knowledge–the first pilot randomised trial of a VR scenario designed specifically for adult smokers unmotivated to stop. Future work would benefit from optimising the VR scenario through, for example, think aloud methodology and then proceed to a larger-scale evaluation study.

1. Introduction

Smoking is a leading cause of premature ill-health and death, directly responsible for >7 million global deaths per year [1]. Supporting smokers to quit is a public health priority. Motivation to stop smoking is a key predictor of quit attempts, with approximately 80–85% of smokers in England characterised as not highly motivated (i.e., not expressing an intention to stop in the next three months) [2,3]. Although population-level mass media campaigns have been found to successfully prompt quit attempts [4], individual-level interventions designed specifically for smokers unmotivated to quit remain scarce [5]. Available individual-level interventions for smokers unmotivated to quit via, for example, video messaging have had limited success in prompting quit attempts [6]. Virtual reality (VR) may offer an innovative and immersive means of delivering more salient stop smoking messaging to people unmotivated to quit, with a view to prompting quit attempts that would otherwise not occur. We therefore conducted a pilot randomised trial to i) assess the feasibility of recruitment and acceptability of a brief, theory-informed VR scenario and ii) estimate proximal quitting outcomes in smokers unmotivated to quit.

VR refers to the creation of a digital environment that has the potential to evoke strong sensory experiences, accessed through increasingly widespread technologies such as head-mounted displays [7]. Although feelings of immersion (e.g., transportation to a different, virtual environment, losing track of time) are characteristic of VR more broadly, the level of immersion experienced by users differs depending on the specific technology used, the number of senses engaged (e.g., vision, hearing, smell) and the level of interactivity (e.g., whether users can interact with objects in the virtual environment through, for example, a joystick) [8]. The potential of VR for delivering interventions to people with mental health problems, including substance use, has received ample attention in the last decade [7,916]. However, few clinical trials have been conducted, and VR deployments for substance use–including smoking cessation–tend to have focused on the delivery of cue exposure therapy. For example, a meta-analysis of 18 studies with 541 smokers found that VR environments in which participants were exposed to smoking-related cues (as compared with scenarios without such cues) reliably induced smoking urges [14]. However, few studies have explored the potential of VR for delivering motivational messaging to smokers unmotivated to quit. A feasibility and pilot study explored the effect of a motivational VR scenario focused on the progression of smoking-related disease in smokers unmotivated to stop; however, this study was limited to young adult smokers who completed the testing within a laboratory setting [17].

We therefore helped develop an immersive, brief VR scenario–suited for delivery in smokers’ own homes and accessible via commercially available head-mounted displays without involving a joystick–grounded in the Extended Parallel Process Model (EPPM) [18]. The EPPM proposes that the effect of threatening health messages (e.g., information or communications highlighting that smoking causes lung cancer) on people’s motivation to protect themselves against said threat (e.g., through behaviour change) depends on two things: 1) people’s emotional responses to the message, and 2) their response- and self-efficacy beliefs (i.e., beliefs that the suggested action to avoid the threat is effective and that one has the ability to act). Previous research guided by the EPPM involving pictorial health warning labels on cigarette packages has found an association of greater self-efficacy and stronger emotional responses to health warning labels with prospective quit attempts [19]. We therefore developed a hospital-based VR scenario, in which participants are invited to attend a consultation with a chest physician in a hospital clinic room and are told that they have had an abnormal chest scan which requires follow-up (i.e., a threatening health message). They are subsequently presented with a brief, written message to boost their response- and quitting self-efficacy. The hypothesised mechanism of action of the EPPM-based scenario is increased susceptibility to smoking-related diseases (i.e., a health threat) combined with increased response- and quitting self-efficacy, which are jointly expected to increase participants’ intention to stop smoking. With regards to the level of immersion, users are not able to interact with the physician via, for example, a joystick and the primary senses engaged are vision and hearing (but not smell, taste or haptics).

Following user testing but prior to conducting a large-scale randomised controlled trial, we considered it important to conduct a pilot trial to assess the feasibility of recruitment and acceptability of the VR scenario. Acceptability of digital health interventions is a multifaceted concept, with available frameworks converging on the view that acceptability captures people’s affective and cognitive attitudes towards a given digital health intervention [20,21]. Specifically, this pilot randomised trial aimed to address the following research questions (RQs):

  • RQ1: Is it feasible to recruit smokers unmotivated to quit with access to a VR headset to take part in a randomised trial?

  • RQ2: In smokers unmotivated to stop, is a VR scenario that emphasises the health consequences of smoking perceived as acceptable?

  • RQ3: Does an active, compared with a ‘sham’, VR scenario lead to greater i) perceived susceptibility to smoking-related diseases; ii) perceived response-efficacy; iii) perceived quitting self-efficacy; and iv) intention to stop smoking (as measured with a behavioural indicator)?

2. Methods

2.1 Study design

The CONSORT checklist of pilot trials [22] was used to inform the study design and write-up (see S1 CONSORT Checklist). This was a parallel-arm, pilot randomised trial conducted remotely with unmotivated, adult smokers randomised to the intervention and control arms in a 1:1 ratio using block randomisation (block size = 5). The random sequence was generated by the first author in R v.3.6.3 using the blockrand package [23]. According to the National Institute for Health Research, pilot studies are “a smaller version of the main study used to test whether the components of the main study can all work together” [24]. The study protocol and analysis plan were pre-registered on the Open Science Framework (osf.io/95tus). We aimed to recruit a total of 60 participants (30 in each arm). For pilot studies, sample sizes between 24 and 50 participants have been recommended [2527]. We aimed to recruit an additional 10 participants to account for potential study dropout. This study was single blinded (i.e., participants were not aware of the group allocation).

2.2 Eligibility criteria

2.2.1 Inclusion criteria

Participants were eligible to take part if they: i) were aged 18+ years; ii) were a fluent English speaker; iii) were a daily or non-daily smoker; iii) were considered ‘unmotivated’ to stop smoking in the next three months (i.e., a Motivation To Stop Scale (MTSS) score of ≤5; [3,28]); iv) had access to a VR headset capable of running the YouTube app (without or with the help of a smartphone); v) were willing and able to meet with a researcher to complete the online testing via teleconferencing software (e.g., Microsoft Teams, Zoom); and vi) had corrected-to-normal vision.

2.2.2 Amendments to the inclusion criteria

Due to a slower than expected recruitment rate, the inclusion criteria were amended in April 2021 (registered on the OSF prior to implementation; osf.io/5xzru/) to no longer restrict recruitment to participants with access to a VR headset. Instead, participants residing in the United Kingdom (UK) who were willing to be gifted an inexpensive headset (i.e., Google Cardboard worth ~£7) via post were also eligible to take part. The geographical limit was set to reduce postal costs, reduce delay between consenting and receipt of the headset, and minimise the testing burden caused by time differences between researchers and participants in different time zones.

2.2.3 Exclusion criteria

Given the nature of the hospital-based VR scenario, which aimed to increase smokers’ perceived susceptibility to cancer (described in detail in section 2.5 below), we did not judge it ethical to include participants with a cancer diagnosis. Therefore, these participants were not eligible to take part, assessed by asking: “Have you been diagnosed with cancer?”. For a similar reason, participants with severe health anxiety were not eligible, determined by a score of ≥5 on the validated 14-item Whitely Index [29,30].

2.3 Sample recruitment

Participants were recruited by adverts stating that the researchers were looking for smokers to provide feedback on a brief VR scenario, which mentioned a gift voucher to reimburse participants for their time. Adverts were placed on social media (i.e., Twitter, Facebook, Reddit), Prolific (www.prolific.co), e-mails sent through university mailing lists, and the researchers’ networks.

2.4 Measures and procedure

Interested participants were asked to complete screening questions relating to the above eligibility criteria via a brief online survey, hosted by Qualtrics. They were also asked to provide information about their i) country of residence, ii) gender (male, female, in another way), iii) occupational status (manual, non-manual, other), iv) whether they owned a VR headset (no, yes), v) type of VR headset (free text response), vi) experience with VR headsets (none, limited, some, substantial), vii) cigarettes smoked per day (CPD), viii) time to first cigarette (TTFC), ix) whether they had made any serious attempts to stop smoking in the past year, and x) whether they had ever used one or more behavioural and/or pharmacological stop smoking aids from a list of options (i.e., nicotine replacement therapy, varenicline, bupropion, e-cigarettes, group counselling, individual counselling, telephone helpline, written materials, website, app).

In the first recruitment phase (prior to the amendment to send headsets), eligible participants were randomised via Qualtrics’ block randomisation function to the intervention or control arms. They were subsequently invited via e-mail to complete the online testing with a researcher present via videoconferencing software. When booking the meeting, participants received instructions to have their smartphone and/or VR headset charged and ready for the online testing. Instructions were identical for intervention and control participants. Reminders to book a meeting were sent to control and intervention participants with equal frequency (i.e., two reminders).

In the second recruitment phase (following the amendment to send headsets), participants who indicated that they did not have access to a VR headset were asked to meet with the researcher twice: first to provide their personal details (i.e., name, postal address, contact number) to enable the researcher to order a VR headset via Amazon to be delivered to the participant, and second to complete the online testing. After having booked a meeting to complete the online testing (irrespective of whether participants were sent a headset), participants were randomised to the intervention or control arms.

During the online testing, participants allocated to the intervention arm were asked to search for and view the active VR scenario within the YouTube app. Participants allocated to the control arm were asked to search for and view the ‘sham’ scenario. Immediately after viewing the VR scenario, participants were asked to complete a post-test survey, hosted by Qualtrics.

First, acceptability was examined by assessing participants’ affective and cognitive attitudes towards the respective scenarios [21]. As both the intervention and control scenarios were delivered in VR, we aimed to assess the acceptability of the specific content delivered in VR format (i.e., there were no 2D controls to examine the comparative acceptability of VR per se). Although there is no consensus definition of acceptability, we recently proposed that acceptability may usefully be considered an emergent property of a complex, adaptive system of multiple, interacting components (e.g., beliefs, knowledge), which is experienced by the individual as a gut reaction or sudden insight [20]. Until further questionnaire development and validation work has been conducted, we reasoned that this sudden insight may be usefully operationalised as affective and cognitive attitudes. Affective attitude was measured by asking participants to rate their agreement with the following statements on a 7-point Likert scale (i.e., ‘strongly disagree’ to ‘strongly agree’): “The scenario made me feel angry”; “The scenario made me feel distressed”. Cognitive attitude was measured by asking participants to rate their agreement with the following statement on a 7-point Likert scale (i.e., ‘strongly disagree’ to ‘strongly agree’): “The scenario was useful to me”. Responses were coded as ‘acceptable’ if participants selected ‘disagree’ or ‘strongly disagree’ for the affective attitude, and ‘agree’ or ‘strongly agree’ for the cognitive attitude, and ‘unacceptable’ otherwise. These items were developed for the purposes of the present study and have not been validated.

Second, participants were asked to provide a rating of their perceived susceptibility to smoking-related diseases, perceived response-efficacy and perceived quitting self-efficacy. Perceived susceptibility was measured with three items: “What do you think your likelihood is of developing (or if you have, the worsening of) the following diseases if you continue smoking?” i) cancer, ii) heart disease, and iii) lung disease. Each were assessed on a 5-point Likert scale (i.e., ‘not at all’ to ‘very likely’) [31]. Responses were coded as ‘susceptible’ (‘moderately likely’ or ‘very likely’) or ‘not susceptible’ (all other response options). Perceived response-efficacy was measured on a 5-point Likert scale (‘strongly disagree’ to ‘strongly agree’) with the following items: “Quitting smoking is an effective protector against cancer”; “Quitting smoking is an effective protector against heart disease”; and “Quitting smoking is an effective protector against lung disease.” Due to a coding error when setting up the Qualtrics survey, 7-point (rather than 5-point) Likert scales were used (‘strongly disagree’ to ‘strongly agree’). Responses were coded as ‘confident’ (‘agree’ or ‘strongly agree’) or ‘not confident’ (all other response options). Perceived quitting self-efficacy was measured on a 5-point Likert scale (i.e., ‘not at all’ to ‘extremely’) with the following item: “How confident are you in your ability to abstain from smoking?” [32]. Responses were coded as ‘confident’ (‘very’ or ‘extremely’) or ‘not confident’ (all other response options).

Participants were then presented with a link to a website with additional, evidence-based information about smoking cessation (http://www.nhs.uk/smokefree). A record was made if a participant clicked on the link provided–the act of clicking was interpreted as a behavioural indicator of intention to stop smoking.

As compensation for their time, participants with their own headset received a £5 gift voucher (or equivalent payment via Prolific) upon completion of the study. Participants without a headset were gifted a cardboard headset (~£7).

2.5 Intervention

2.5.1 Intervention–active VR scenario

The active VR scenario was informed by the Extended Parallel Process Model [18] and was developed by an independent software developer (‘MasterChange’) with input from the researchers. In the immersive scenario, participants are invited to attend a consultation with a chest physician in a hospital clinic room (see Fig 1). Participants are told by the chest physician that they have had an abnormal chest scan which requires follow-up. They are subsequently presented with a brief, written message to boost their response- and quitting self-efficacy (i.e., “Stopping smoking is the single most important thing that you can do to improve your health and quality of life. We now know that the best way to stop is the combination of support, advice and stop smoking treatments provided by your local stop smoking services. The expert service will greatly increase your chances of success and is available for free. Millions of people in England have stopped with their help. They were just like you. Believe in yourself and commit to quitting today!"). See S1 Data for the behaviour change techniques (BCTs) included in the intervention scenario, coded against a 44-item taxonomy of BCTs used in behavioural smoking cessation interventions [33]. The hypothesised mechanism of action of the scenario is increased susceptibility to smoking-related diseases combined with increased response- and quitting self-efficacy, which are jointly expected to increase participants’ intention to stop smoking. Evidence suggests that fear appeals tend to undermine behaviour change unless they are also accompanied by materials that boost participants’ self-efficacy [34]. Due to the potential of VR to evoke strong sensory and emotional experiences–e.g., prior research shows it can reliably induce smoking urges [14]–we expected the immersive VR scenario to evoke strong emotional responses to the health message. Although we did not include a 2D video control, we expected emotional responses to be stronger than if, for example, viewing a 2D video with the same health message.

Fig 1. Screenshot of the active VR scenario.

Fig 1

Reproduced with permission from MasterChange.

2.5.2 Control–‘sham’ VR scenario

Participants allocated to the control arm were asked to view an immersive VR scenario of equivalent length about the human body, developed by ‘Hybrid Medical’ (see Fig 2). The content of the scenario was neutrally framed. This was deemed a suitable control condition as it exposes participants to the same immersive VR environment for a similar length of time but without providing any smoking-specific messaging.

Fig 2. Screenshot of the ‘sham’ VR scenario.

Fig 2

Reproduced with permission from Hybrid Medical.

Formative user testing of the intervention and control scenarios and the study materials was conducted in December 2020. The feedback received was used to improve the study materials (i.e., enhancing the visibility of the weblink to the additional stop smoking information by increasing the font size).

2.6 Ethical approval

The study fell within the scope of ‘The optimisation and implementation of interventions to change behaviours related to health and the environment’, approved by UCL’s Research Ethics Committee (Project ID: CEHP/2020/579). Prior to taking part, participants were asked to read an information sheet detailing the study procedures and provide electronic informed consent, including consent for their fully anonymised data to be shared on an open science repository.

2.7 Data analysis

The analyses were conducted in R v.3.6.3. Descriptive statistics (means, percentages) were calculated to describe the sample.

To address RQ1, we considered a large-scale randomised controlled trial (RCT) of the brief VR scenario feasible to deliver if we were able to recruit the target sample size of 60 participants within three months from the trial start date (i.e., January 2021). The feasibility target was selected on the basis of the following assumptions/considerations: i) recruitment for a large-scale RCT would ideally be completed within two years, and ii) expecting a three-fold increase in the rate of recruitment with added resource (i.e., a full- as opposed to part-time researcher working on the project in addition to a budget of £2.50 per recruited participant via Facebook advertising, or a total of £4000). A power simulation in R (nsims = 500) indicated that a sample size of 1562 participants would provide >80% power (with one-tailed alpha set to 5%) to detect a projected 5% increase in quit attempts at a 6-month follow-up in the intervention arm compared with the ‘sham’ control (i.e., 25% vs. 20%, OR = 1.25). The anticipated effect size is based on what is known about the rate of unaided quit attempts in the past 6 months in England (www.smokinginengland.info)–removing highly motivated people–and a previous intervention for unmotivated smokers, which yielded a 9% intervention difference in quit attempts at 6 months [5]. As our brief VR scenario is judged to be less intensive than the intervention provided in Carpenter et al. (2011), we anticipate a slightly smaller intervention difference of 5%. Therefore, based on the above assumptions, being able to recruit 60 participants within three months from the trial start date (or ~200 participants with added resource), this would ensure we would be able to recruit ~1600 participants within 24 months from the trial start date.

2.8 Deviations from the pre-specified analysis plan

To address RQs 2–3, we had specified in the pre-registered analysis plan that linear and logistic regression analyses would be conducted to examine group differences in acceptability, perceived susceptibility to smoking-related diseases, perceived response-efficacy, perceived quitting self-efficacy, and intention to stop smoking. However, following statistical review but before completing data collection, we deemed it more appropriate to instead calculate point estimates and 95% confidence intervals (CIs) due to the small sample size, opting for a more descriptive approach. As a result of the peer review process, however, we also present results from linear regression analyses with the outcome variables (except for intention to stop smoking) operationalised as continuous in Table A in S1 Table. We also present the bivariate correlations between the acceptability and perceived susceptibility indicators in Table B in S1 Table.

3. Results

3.2 Participant characteristics

A total of 614 participants completed the screening, of whom 376 (61.2%) were eligible to take part. A total of 103 (16.8%) participants responded to the invitation to attend the online testing session and were randomised, with 62 attending the testing session and completing the study (10.1%). Due to a technical glitch, post-task survey data were lost for two participants (intervention: n = 1; control: n = 1), leaving an analytic sample of 60 participants (see Fig 3). The mean age of participants was 34.4 (12.1) years, with 46.7% identifying as female (see Table 1). Most participants were residing in the United Kingdom and half had a non-manual occupation.

Fig 3. CONSORT flow diagram of the study participants.

Fig 3

Table 1. Participant demographic and smoking characteristics (analytic sample, N = 60).

Total (N = 60) Intervention (n = 30) Control (n = 30)
Age, mean (SD) 34.4 (12.1) 35.9 (13.6) 32.9 (10.3)
Gender, n (%)
    Female 28 (46.7%) 17 (56.7%) 11 (36.7%)
    Male 32 (53.3%) 13 (43.3%) 19 (63.3%)
Occupational status, n (%)
    Manual 13 (21.7%) 6 (20.0%) 7 (23.3%)
    Non-manual 30 (50.0%) 14 (46.7%) 16 (53.3%)
    Other (student, unemployed, retired) 17 (28.3%) 10 (33.3%) 7 (23.3%)
Country, n (%)
    United Kingdom 48 (80.0%) 22 (73.3%) 26 (86.7%)
    Austria 1 (1.7%) 1 (3.3%) 0 (0.0%)
    Canada 2 (3.3%) 1 (3.3%) 1 (3.3%)
     Greece 1 (1.7%) 0 (0.0%) 1 (3.3%)
     Hungary 1 (1.7%) 0 (0.0%) 1 (3.3%)
     India 1 (1.7%) 0 (0.0%) 1 (3.3%)
     Italy 2 (3.3%) 2 (6.7%) 0 (0.0%)
    Poland 1 (1.7%) 1 (3.3%) 0 (0.0%)
     South Africa 1 (1.7%) 1 (3.3%) 0 (0.0%)
     Spain 1 (1.7%) 1 (3.3%) 0 (0.0%)
     United States 1 (1.7%) 1 (3.3%) 0 (0%)
Cigarettes per day, mean (SD) 9.8 (7.2) 11.3 (7.6) 8.4 (6.5)
Time to first cigarette, n (%)
     <5 minutes 7 (11.7%) 4 (13.3%) 3 (10.0%)
 6–30 minutes 27 (45.0%) 15 (50.0%) 12 (40.0%)
     31–60 minutes 6 (10.0%) 2 (6.7%) 4 (13.3%)
     60+ minutes 20 (33.3%) 9 (30.0%) 11 (36.7%)
Motivation to stop, n (%)
     I don’t want to stop smoking 21 (35.0%) 9 (30.0%) 12 (40.0%)
     I think I should stop smoking but don’t really want to 27 (45.0%) 16 (53.3%) 11 (36.7%)
     I want to stop smoking but haven’t thought about when 8 (13.3%) 3 (10.0%) 5 (16.7%)
     I really want to stop smoking but I don’t know when I will 4 (6.7%) 2 (6.7%) 2 (6.7%)
Quit attempt(s), n (%)
     No, never 27 (45.0%) 9 (30.0%) 18 (60.0%)
     Yes, but not in the past year 26 (43.3%) 17 (56.7%) 9 (30.0%)
     Yes, in the past year 7 (11.7%) 4 (13.3%) 3 (10.0%)
Ever use of behavioural support, n (%)
     No 48 (80.0%) 22 (73.3%) 26 (86.7%)
     Yes 12 (20.0%) 8 (26.7%) 4 (13.3%)
Ever use of pharmacological support, n (%)
     No 32 (53.3%) 15 (50.0%) 17 (56.7%)
     Yes 28 (46.7%) 15 (50.0%) 13 (43.3%)
Own headset, n (%)
     No 31 (51.7%) 15 (50.0%) 16 (53.3%)
     Yes 29 (48.3%) 15 (50.0%) 14 (46.7%)
VR headset type, n (%)
     Google Cardboard 6 (10.0%) 1 (3.3%) 5 (16.7%)
     Homido 1 (1.7%) 1 (3.3%) 0 (0.0%)
     Oculus Quest/Rift 7 (11.7%) 3 (10.0%) 4 (13.3%)
     PlayStation VR 2 (3.3%) 0 (0.0%) 2 (6.7%)
     Populous 1 (1.7%) 0 (0.0%) 1 (3.3%%)
     Utopia 360 1 (1.7%) 1 (3.3%) 0 (0.0%)
     Trust 1 (1.7%) 1 (3.3%) 0 (0.0%)
     Don’t know/not reported/does not own a headset 41 (68.3%) 23 (76.7%) 18 (60%)
Past VR experience, n (%)
     None 12 (20.0%) 7 (23.3%) 5 (16.7%)
     Limited 23 (38.3%) 13 (43.3%) 10 (33.3%)
     Some 19 (31.7%) 8 (26.7%) 11 (36.7%)
     Substantial 6 (10.0%) 2 (6.7%) 4 (13.3%)

Note. SD = standard deviation.

3.3 Feasibility of recruitment

A total of 62 participants (intervention: n = 31; control: n = 31) were randomised and completed the testing within 7 months from the trial start date (February-August 2021), 39 of whom were recruited within 2 months of active recruitment (rather than calendar time) following an amendment to gift inexpensive headsets, sent to participants via post. Due to the need for a protocol amendment, the study was first paused to await ethical approval and next paused for a couple of weeks when the researchers were on leave for the summer holidays. We therefore consider here only the active recruitment periods.

3.4 Acceptability

The intervention (86.7%, 95% CI = 69.3%-96.2%) and control (93.3%, 95% CI = 77.9%-99.2%) scenarios were rated as acceptable. In the sensitivity analysis with the acceptability indicators operationalised as continuous variables, there were no significant differences between the intervention and control scenarios (Table A in S1 Table).

3.5 Proximal quitting outcomes

Proximal quitting outcomes in the intervention and control arm were comparable (see Table 2). In the sensitivity analysis with the proximal quitting outcomes operationalised as continuous variables (except for intention to stop), there were no significant differences between the intervention and control scenarios, with the exception of quitting self-efficacy (see S1 Table). Quitting self-efficacy was significantly greater in the control (M = 3.03, SD = 1.07) compared with the intervention arm (M = 2.30, SD = 0.95), p = 0.006.

Table 2. Proximal quitting outcomes (analytic sample, N = 60).

Intervention (n = 30) Control (n = 30)
Perceived susceptibility to cancer, % (95% CI)
 Susceptible 93.3% (77.9%-99.2%) 93.3% (77.9%-99.2%)
Perceived susceptibility to heart disease, % (95% CI)
     Susceptible 73.3% (54.1%-87.7%) 86.7% (69.3%-96.2%)
Perceived susceptibility to lung disease, % (95% CI)
     Susceptible 93.3% (77.9%-99.2%) 93.3% (77.9%-99.2%)
Cancer response-efficacy, % (95% CI)
     Confident 80.0% (61.4%-92.3%) 76.7% (57.7%-90.1%)
Heart disease response-efficacy, % (95% CI)
     Confident 63.3% (43.9%-80.1%) 70.0% (50.6%-85.3%)
Lung disease response-efficacy, % (95% CI)
     Confident 83.3% (65.3%-94.4%) 86.7% (69.3%-96.2%)
Quitting self-efficacy, % (95% CI)
     Confident 13.3% (3.7%-30.7%) 26.7% (12.3%-45.9%)
Behavioural indicator of intention to stop smoking, % (95% CI)
     Yes 3.3% (0.1%-17.2%) 0% (0%-11.6%)

Note. CI = confidence interval.

4. Discussion

This pilot randomised trial aimed to examine the feasibility of recruitment and acceptability of a brief, theory-informed VR scenario and estimate proximal quitting outcomes. The target sample size of 60 participants was not achieved within the pre-specified feasibility window. However, an amendment to gift inexpensive VR headsets, sent to UK participants via post, appeared promising. This resulted in the recruitment of ~62% of the sample within two months of active recruitment. The intervention and control VR scenarios alike were rated as acceptable by participants. As it may be perceived as sensitive to raise the topic of smoking cessation to smokers unmotivated to stop, we consider the results pertaining to acceptability particularly promising. The perceived susceptibility and response-efficacy to cancer, heart disease, and lung disease were comparably high across arms, which may be indicative of a ceiling effect (i.e., participants already felt moderately to highly susceptible). Quitting self-efficacy and intention to stop smoking were comparably low across arms. There are different plausible interpretations of this finding. First, the brief VR scenario may have been insufficiently immersive or persuasive for boosting smokers’ self-efficacy and therefore also their motivation to stop. Second, smokers may have slightly rushed through the post-task survey and hence missed the link with more information about smoking cessation. This merits further exploration in, for example, a study using think aloud methodology, with smokers verbalising their thoughts and impressions whilst viewing the VR scenario.

Prior smoking cessation research using VR technology has primarily focused on the delivery of cue exposure therapy [14], with the exception of a pilot study of a motivational VR scenario for young adults focused on the progression of smoking-related disease [17]. More recently, however, Machulska and colleagues conducted an RCT of a VR-based approach bias retraining programme, with no significant effects on approach bias or daily cigarette consumption detected at a 7-week follow-up [35]. Since the planning and conduct of the present study, VR technology has been used to deliver educational games to high school students, with a view to preventing smoking initiation [36]. In addition, VR technology has been used to deliver post-retrieval extinction therapy to disrupt smoking memory reconsolidation and prevent future cravings, with positive preliminary results [37]. However, large-scale trials of VR deployments for smoking cessation with long-term follow-ups (e.g., 6 or 12 months) remain scarce.

4.1 Strengths and limitations

This study was strengthened by including the element of randomisation, with participants allocated to view either an active or a ‘sham’ VR scenario. In addition, the VR scenarios were delivered in smokers’ own homes, thus mimicking real-world conditions, and ensuring ecological validity of the procedures and results.

However, this study also had several limitations. First, as illustrated by the initially slow recruitment, smokers do not yet appear to have easy access to VR headsets. Until VR headsets are more ubiquitous among the general population of smokers, the potential for VR to deliver motivational messaging in smokers’ own homes is limited. In addition, as most of our sample had at least some prior VR experience, this raises the question as to whether an immersive VR scenario focused on the health consequences of smoking may be more salient to those using VR for the first time (i.e., a potential novelty effect) [38,39]. Second, the effective point of randomisation occurred when participants booked a meeting to complete the online testing (with intervention and control participants receiving the same instructions), with many participants dropping out at this stage (i.e., not attending the testing). Although not statistically significant, this led to group imbalances in the baseline sociodemographic and smoking characteristics. Although this did not compromise the randomisation itself (as participants had received identical instructions, with drop-outs unrelated to group allocation), future studies should aim to randomise participants as close to participation as possible (e.g., when attending the testing session). Third, our active VR scenario was not highly interactive (i.e., albeit immersive, smokers were unable to communicate with the chest physician through a joystick or similar tools). This may have negatively influenced feelings of immersion and hence also smokers’ affective responses to the scenario, which may in turn have been insufficient for boosting their motivation to stop [8]. However, the findings pertaining to the proximal quitting outcomes ought to be interpreted with caution, as the study was not powered to detect group differences in smokers’ perceptions and intentions. Fourth, to ensure that participants completed the task as instructed, a researcher was present during the testing via teleconferencing software. This may have influenced participants’ willingness to click on the link with additional information about smoking cessation (which was used to capture their intention to stop)–i.e., they may have slightly rushed through the post-task survey. Fifth, the focus on proximal quitting outcomes (e.g., intention to stop) is limited by the well-known intention-behaviour gap (i.e., strong intentions often do not translate to actual behaviour change) [40]. Therefore, future work would benefit from capturing quit attempts and quit success in addition to perceptions and intentions. Sixth, the items used to capture acceptability and intention to stop smoking were developed for the purposes of the present study and had not been validated. Though, we have previously used a similar behavioural indicator of intention to change in a different behaviour change context [41] and we note that prior research has found a positive association between intention to change and information seeking/user engagement in digital health research [42]. With regards to the definition and operationalisation of intervention acceptability, this remains a debated topic and we have previously argued that acceptability can usefully be conceptualised as an emergent property of a complex, adaptive system of interacting subcomponents (e.g., cognitive and affective attitude) [20]. However, it should be noted that there may be some degree of overlap between acceptability as operationalised in the present study (e.g., anger, distress, perceived usefulness) and the emotional reactions expected to be elicited by the VR scenario (e.g., fear, worry)–which in turn were expected to influence perceived susceptibility to cancer/heart disease/lung disease. Although correlations between the acceptability and susceptibility indicators were small in magnitude and non-significant (presented in Table B in S1 Table), further conceptual and psychometric work is required to refine the acceptability measure and evaluate its validity and reliability (including the identification of a suitable cut-off score across the three indicators). In addition, future research would benefit from assessing the prospective validity of behavioural indicators of intention (i.e., whether website clicks are associated with self-reported smoking cessation attempts measured at a later time point). Finally, due to a coding error when setting up the Qualtrics survey, the validated scale used to capture response-efficacy was measured using seven (instead of five) response options.

4.2 Implications and avenues for future research

Until VR headsets become more widespread among the general population of smokers, providing smokers with a simple headset (<£10) appears promising. Alternatively, the opportunistic delivery of immersive stop smoking messaging in settings other than smokers’ homes (e.g., general practice or dentist waiting rooms) merits further investigation. In addition, prior to conducting a larger-scale study, we recommend optimising the VR scenario through drawing on user-centred design principles, identifying ways to make the active VR scenario more interactive and immersive, and better understanding smokers’ experiences of an optimised scenario (including the motivational message itself) through think aloud methodology [4345]. Areas of improvement may, for example, include the addition of functionality to allow users to directly interact/communicate with the physician (e.g., through selecting different communication options via a joystick). Future work would also benefit from formalising some of the insights gleaned about users’ experiences from informal conversations with participants at the end of testing sessions through qualitative methods.

4.3 Conclusions

This was, to our knowledge, the first pilot randomised trial of a VR scenario designed specifically for adult smokers unmotivated to stop. The target sample size was not achieved within the feasibility window; however, an amendment to gift inexpensive VR headsets appeared promising. The VR scenario appeared acceptable. Future work would benefit from optimising the VR scenario prior to conducting a larger-scale study.

Supporting information

S1 CONSORT Checklist. CONSORT checklist of information to include when reporting a pilot or feasibility trial.

(DOC)

S1 Data. Behaviour change techniques (BCTs) included in the intervention scenario, coded against a 44-item taxonomy of BCTs used in behavioural smoking cessation interventions [33].

(XLSX)

S1 Table. Results from linear regression analyses with the outcome variables (except for intention to stop smoking) operationalised as continuous in addition to the bivariate correlations between the acceptability and perceived susceptibility indicators.

(DOCX)

Acknowledgments

We gratefully acknowledge the funding listed above. The researchers would like to thank Nick Abelson from MasterChange and Dr. Matt Evison for providing access to the active VR scenario and HybridMedical for providing access to the control scenario.

Data Availability

The data underpinning the analyses are openly available via Zenodo: https://doi.org/10.5281/zenodo.5747705. The R code is openly available via GitHub: https://github.com/OlgaPerski/VR_study.

Funding Statement

OP, DK, and TJ receive salary support from Cancer Research UK (C1417/A22962). JB, OP, DK and TJ are members of SPECTRUM – a UK Prevention Research Partnership Consortium (MR/S037519/1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.World Health Organisation. WHO report on the global tobacco epidemic 2021: addressing new and emerging products. 2021. Available: https://www.who.int/teams/health-promotion/tobacco-control/global-tobacco-report-2021 [Google Scholar]
  • 2.Brose LS, Brown J, Robson D, McNeill A. Mental health, smoking, harm reduction and quit attempts–a population survey in England. BMC Public Health. 2020;20: 1237. doi: 10.1186/s12889-020-09308-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Kotz D, Brown J, West R. Predictive validity of the Motivation To Stop Scale (MTSS): A single-item measure of motivation to stop smoking. Drug and Alcohol Dependence. 2013;128: 15–19. doi: 10.1016/j.drugalcdep.2012.07.012 [DOI] [PubMed] [Google Scholar]
  • 4.Richardson S, Langley T, Szatkowski L, Sims M, Gilmore A, McNeill A, et al. How does the emotive content of televised anti-smoking mass media campaigns influence monthly calls to the NHS Stop Smoking helpline in England? Preventive Medicine. 2014;69: 43–48. doi: 10.1016/j.ypmed.2014.08.030 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Carpenter MJ, Hughes JR, Gray KM, Wahlquist AE, Saladin ME, Alberg AJ. Nicotine Therapy Sampling to Induce Quit Attempts Among Smokers Unmotivated to Quit: A Randomized Clinical Trial. JAMA Internal Medicine. 2011;171: 1901–1907. doi: 10.1001/archinternmed.2011.492 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Brown J, Michie S, Walmsley M, West R. An Online documentary film to motivate quit attempts among smokers in the general population (4Weeks2Freedom): A randomized controlled trial. Nicotine and Tobacco Research. 2016;18: 1093–1100. doi: 10.1093/ntr/ntv161 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Fox J, Arena D, Bailenson JN. Virtual Reality: A Survival Guide for the Social Scientist. Journal of Media Psychology. 2009;21: 95–113. doi: 10.1027/1864-1105.21.3.95 [DOI] [Google Scholar]
  • 8.Miller HL, Bugnariu NL. Level of Immersion in Virtual Environments Impacts the Ability to Assess and Teach Social Skills in Autism Spectrum Disorder. Cyberpsychol Behav Soc Netw. 2016;19: 246–256. doi: 10.1089/cyber.2014.0682 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Bordnick PS, Carter BL, Traylor AC. What virtual reality research in addictions can tell us about the future of obesity assessment and treatment. Journal of Diabetes Science and Technology. 2011;5: 265–271. doi: 10.1177/193229681100500210 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Freeman D, Reeve S, Robinson A, Ehlers A, Clark D, Spanlang B, et al. Virtual reality in the assessment, understanding, and treatment of mental health disorders. Psychological Medicine. 2017;47: 2393–2400. doi: 10.1017/S003329171700040X [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Ghiţă A, Gutiérrez-Maldonado J. Applications of virtual reality in individuals with alcohol misuse: A systematic review. Addictive Behaviors. 2018;81: 1–11. doi: 10.1016/j.addbeh.2018.01.036 [DOI] [PubMed] [Google Scholar]
  • 12.Jerdan SW, Grindle M, Van Woerden HC, Kamel Boulos MN. Head-mounted virtual reality and mental health: Critical review of current research. Journal of Medical Internet Research. 2018;20: 1–12. doi: 10.2196/games.9226 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Mishkind MC, Norr AM, Katz AC, Reger GM. Review of Virtual Reality Treatment in Psychiatry: Evidence Versus Current Diffusion and Use. Current Psychiatry Reports. 2017;19. doi: 10.1007/s11920-017-0836-0 [DOI] [PubMed] [Google Scholar]
  • 14.Pericot-Valverde I, Germeroth LJ, Tiffany ST. The Use of Virtual Reality in the Production of Cue-Specific Craving for Cigarettes: A Meta-Analysis. Nicotine and Tobacco Research. 2016;18: 538–546. doi: 10.1093/ntr/ntv216 [DOI] [PubMed] [Google Scholar]
  • 15.Spagnolli A, Bracken CC, Orso V. The role played by the concept of presence in validating the efficacy of a cybertherapy treatment: A literature review. Virtual Reality. 2014;18: 13–36. doi: 10.1007/s10055-013-0241-x [DOI] [Google Scholar]
  • 16.Trahan MH, Maynard BR, Smith KS, Farina ASJ, Khoo YM. Virtual Reality Exposure Therapy on Alcohol and Nicotine: A Systematic Review. Research on Social Work Practice. 2019;29: 876–891. doi: 10.1177/1049731518823073 [DOI] [Google Scholar]
  • 17.Caponnetto P, Maglia M, Lombardo D, Demma S, Polosa R. The role of virtual reality intervention on young adult smokers’ motivation to quit smoking: a feasibility and pilot study. Journal of Addictive Diseases. 2018;37: 217–226. doi: 10.1080/10550887.2019.1664364 [DOI] [PubMed] [Google Scholar]
  • 18.Witte K. Putting the fear back into fear appeals: The extended parallel process model. Communication Monographs. 1992;59: 329–349. doi: 10.1080/03637759209376276 [DOI] [Google Scholar]
  • 19.Thrasher JF, Swayampakala K, Borland R, Nagelhout G, Yong H, Hammond D, et al. Influences of Self-Efficacy, Response Efficacy, and Reactance on Responses to Cigarette Health Warnings: A Longitudinal Study of Adult Smokers in Australia and Canada. Health Communication. 2016;31: 1517–1526. doi: 10.1080/10410236.2015.1089456 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Perski O, Short CE. Acceptability of digital health interventions: embracing the complexity. Translational Behavioral Medicine. 2021;11: 1473–1480. doi: 10.1093/tbm/ibab048 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: An overview of reviews and development of a theoretical framework. BMC Health Services Research. 2017;17: 1–13. doi: 10.1186/s12913-017-2031-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: Extension to randomised pilot and feasibility trials. British Medical Journal. 2016;355: i5239. doi: 10.1136/bmj.i5239 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Snow G. Package “blockrand.” 2020. Available: https://cran.r-project.org/web/packages/blockrand/blockrand.pdf [Google Scholar]
  • 24.National Institute for Health Research. Glossary. 2020 [cited 9 Apr 2020]. Available: https://www.nihr.ac.uk/about-us/glossary.htm?letter=P&postcategory=-1
  • 25.Hooper R. Justifying sample size for a feasibility study. London; 2019. [Google Scholar]
  • 26.Sim J, Lewis M. The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency. Journal of Clinical Epidemiology. 2012;65: 301–308. doi: 10.1016/j.jclinepi.2011.07.011 [DOI] [PubMed] [Google Scholar]
  • 27.Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharmaceutical Statistics. 2005;4: 287–291. doi: 10.1002/pst.185 [DOI] [Google Scholar]
  • 28.Hummel K, Brown J, Willemsen MC, West R, Kotz D. External validation of the motivation to stop scale (MTSS): Findings from the international tobacco control (ITC) Netherlands survey. European Journal of Public Health. 2016;27: 129–134. doi: 10.1093/eurpub/ckw105 [DOI] [PubMed] [Google Scholar]
  • 29.Pilowsky I. Dimensions of hypochondriasis. The British Journal of Psychiatry. 1967;113: 89–93. doi: 10.1192/bjp.113.494.89 [DOI] [PubMed] [Google Scholar]
  • 30.Hedman E, Lekander M, Ljótsson B, Lindefors N, Rück C, Andersson G, et al. Optimal cut-off points on the health anxiety inventory, illness attitude scales and whiteley index to identify severe health anxiety. PLoS ONE. 2015;10: 1–12. doi: 10.1371/journal.pone.0123412 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Borrelli B, Hayes RB, Dunsiger S, Fava J. Risk Perception and Smoking Behavior In Medically Ill Smokers: A Prospective Study. Addiction. 2010;105: 1100–1108. doi: 10.1111/j.1360-0443.2010.02900.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Shiffman S. Dynamic influences on smoking relapse process. Journal of Personality. 2005;73: 1715–1748. doi: 10.1111/j.0022-3506.2005.00364.x [DOI] [PubMed] [Google Scholar]
  • 33.Michie S, Hyder N, Walia A, West R. Development of a taxonomy of behaviour change techniques used in individual behavioural support for smoking cessation. Addictive Behaviors. 2011;36: 315–319. doi: 10.1016/j.addbeh.2010.11.016 [DOI] [PubMed] [Google Scholar]
  • 34.Peters G-JY, Ruiter RAC, Kok G. Threatening communication: a critical re-analysis and a revised meta-analytic test of fear appeal theory. Health Psychology Review. 2013;7: S8–S31. doi: 10.1080/17437199.2012.703527 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Machulska A, Eiler TJ, Kleinke K, Grünewald A, Brück R, Jahn K, et al. Approach bias retraining through virtual reality in smokers willing to quit smoking: A randomized-controlled study. Behaviour Research and Therapy. 2021;141: 103858. doi: 10.1016/j.brat.2021.103858 [DOI] [PubMed] [Google Scholar]
  • 36.Guo J-L, Hsu H-P, Lai T-M, Lin M-L, Chung C-M, Huang C-M. Acceptability Evaluation of the Use of Virtual Reality Games in Smoking-Prevention Education for High School Students: Prospective Observational Study. Journal of Medical Internet Research. 2021;23: e28037. doi: 10.2196/28037 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Zandonai T, Benvegnù G, Tommasi F, Ferrandi E, Libener E, Ferraro S, et al. A virtual reality study on postretrieval extinction of smoking memory reconsolidation in smokers. Journal of Substance Abuse Treatment. 2021;125: 108317. doi: 10.1016/j.jsat.2021.108317 [DOI] [PubMed] [Google Scholar]
  • 38.Elor A, Powell MO, Mahmoodi E, Teodorescu M, Kurniawan S. Gaming Beyond the Novelty-Effect of Immersive Virtual Reality for Physical Rehabilitation. IEEE Transactions on Games. 2021; 1–1. doi: 10.1109/TG.2021.3069445 [DOI] [Google Scholar]
  • 39.Rutten I, Bogaert LV den, Geerts D. From Initial Encounter With Mid-Air Haptic Feedback to Repeated Use: The Role of the Novelty Effect in User Experience. IEEE Trans Haptics. 2021;14: 591–602. doi: 10.1109/TOH.2020.3043658 [DOI] [PubMed] [Google Scholar]
  • 40.Sniehotta FF, Presseau J, Araújo-Soares V. Time to retire the theory of planned behaviour. Health Psychology Review. 2014;8: 1–7. doi: 10.1080/17437199.2013.869710 [DOI] [PubMed] [Google Scholar]
  • 41.Perski O, Stevens C, West R, Shahab L. Pilot randomised controlled trial of the Risk Acceptance Ladder (RAL) as a tool for targeting health communications. PLoS One. 2021;16: e0259949. doi: 10.1371/journal.pone.0259949 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Crutzen R, de Nooijer J, Candel MJJM, de Vries NK. Adolescents Who Intend to Change Multiple Health Behaviours Choose Greater Exposure to an Internet-delivered Intervention. J Health Psychol. 2008;13: 906–911. doi: 10.1177/1359105308095064 [DOI] [PubMed] [Google Scholar]
  • 43.Abras C, Maloney-Krichmar D, Preece J. User-Centered Design. Encyclopedia of Human-Computer Interaction. Thousand Oaks: Sage Publications; 2004. pp. 1–14. [Google Scholar]
  • 44.Crane D, Garnett C, Brown J, West R, Michie S. Factors influencing usability of a smartphone app to reduce excessive alcohol consumption: Think aloud and interview studies. Frontiers in Public Health. 2017;5: 1–19. doi: 10.3389/fpubh.2017.00039 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Perski O, Blandford A, Ubhi HK, West R, Michie S. Smokers’ and drinkers’ choice of smartphone applications and expectations of engagement: a think aloud and interview study. BMC Medical Informatics and Decision Making. 2017;17: 1–14. doi: 10.1186/s12911-017-0422-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
PLOS Digit Health. doi: 10.1371/journal.pdig.0000060.r001

Decision Letter 0

Laura M König, Liliana Laranjo

10 Feb 2022

PDIG-D-22-00003

A pilot randomised trial of a brief virtual reality scenario in smokers unmotivated to quit: Assessing the feasibility of recruitment

PLOS Digital Health

Dear Dr. Perski,

Thank you for submitting your manuscript to PLOS Digital Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Digital Health's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The reviewers see potential in your submission, however, they also highlighted a number of issues including:

- a lack of detial in describing immersive VR and the intervention, including behaviour change techniques used

- the decision to dichotomise variables in the analysis

- the discussion being short and not referring at all to research question 3.

Please submit your revised manuscript by Apr 11 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at digitalhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pdig/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

* A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

* A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

* An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Laura M. König

Academic Editor

PLOS Digital Health

Journal Requirements:

1. Please amend your detailed Financial Disclosure statement. This is published with the article, therefore should be completed in full sentences and contain the exact wording you wish to be published.

State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

2. Please update the completed 'Competing Interests' statement. Please declare all competing interests beginning with the statement "I have read the journal's policy and the authors of this manuscript have the following competing interests:"

3. Please provide separate figure files in .tif or .eps format only and remove any figures embedded in your manuscript file. Please ensure that all files are under our size limit of 20MB.

For more information about how to convert your figure files please see our guidelines: https://journals.plos.org/digitalhealth/s/figures

4. We have noticed that you have uploaded supporting information but you have not included a list of legends. Please add a full list of legends for all supporting information files (including figures, table and data files) after the references list.

Additional Editor Comments (if provided):

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does this manuscript meet PLOS Digital Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

Reviewer #3: Yes

--------------------

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: No

Reviewer #3: Yes

--------------------

3. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

--------------------

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Digital Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

--------------------

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thanks for the opportunity to review this interesting manuscript about a novel VR-based strategy to reach and help smokers unmotivated to quit. The manuscript is easy to read and generally offers a sound overview of the research that was conducted. I would advise the authors to take a look at the feedback points below, to make further improvements to their manuscript.

- the introduction is well-written and offers a clear overview of the main concepts and rationale for main choices. At several points, the introduction raises questions, but these are always answered when one continues reading the next sections. So, overall the introduction is on point and well-substantiated with references.

- the methods section includes a rather detailed account of how the pilot trial was set up, how inclusion and recruitment took place, and what data was collected in both study arms. Yet, the section describing the intervention conditions could elaborate more on the specific working mechanism of the immersive VR component (e.g. in comparison to watching a video of a physician talking to you); what makes VR potentially more effective than other kind of media outlets/channels?

- although the results and conclusions seem clear, it would be interesting to read more about potential improvements to the active VR scenario. According to the authors, what may be the most promising application of VR for smoking cessation, and which target population should this be particularly aimed at?

Minor comments

- there is some redundancy in the information provided in the second paragraph of section 2.4 measures and procedures.

- the part describing and justifying the recruitment goal is somewhat confusing: could you make it more explicit how the 60 participants in 3 months goal resulted from the full-trial calculations provided?

- results: could you clarify why only 103 out of 376 eligible participants were randomized?

- results: it is not clear what is meant with the following sentence '39 of whom were recruited within 2 months of active recruitment (rather than calendar time) following an amendment to gift inexpensive headsets, sent to participants via post.' Please consider rephrasing.

Reviewer #2: This study sets out to examine the feasibility and acceptability of a pilot RCT using a brief virtual reality (VR) intervention in 60 smokers unmotivated to stop, randomized to an intervention (motivational VR) or control condition (control VR). Results showed that the targeted sample size was not achieved within the planned time frame, but that the intervention was perceived as acceptable. Preliminary analysis of the intervention effect on motivational constructs showed comparable point estimates in perceived susceptibility, response-efficacy and self-efficacy, and behavioral intention.

Overall, this paper takes an interesting approach using VR to deliver motivational messages. The manuscript is well structured and written and the experimental design is a strength. I however also have several concerns that narrow the impact of the manuscript. Overall, I find that in several instances the paper is rather short on information and appears superficial. I am also struggling that the sample recruitment is treated as the primary outcome and substantive questions which most likely are more relevant for the broader scientific community, are moved into the background. Also, there are several methodological concerns concerning the validity of measures and analysis (e.g., dichotomization). Please see more specific comments below:

Introduction:

- Please elaborate on EPPM and what the theory-basis for the intervention scenario is.

- It is unclear if authors are interested in the acceptability of VR per se or the specific content delivered via VR in the study.

- Please elaborate on the concept of acceptability of digital health interventions as mutlifaceted concept and provide a rationale for why this is operationalized as attitudes.

Methods:

- Please provide citations for where the items stem from and provide reliability coeffients along with descriptive data.

- Why were all measures dichotomized and on what basis? This is in my view highly problematic, resulting in a loss of information, and endangering validity.

- How valid is the behavioral measure of intention? I am not convinced that clicking on additional evidence-based information reflects intention to stop. It is also plausible that smokers who have

been motivated might not think they need further information to make a decision.

- Please elaborate the presented rationale for using point estimates (%). Why was it not possible to conduct regression analyses and report mean level differences and and corresponding CI (instead of P values)?

Discussion:

- There is no discussion of Research Question 3

Minor points:

p. 5: explain why cancer patients were not eligible to take part in the study

p. 11: What is meant by calendar time?

Reviewer #3: This paper provides a clear report of the pilot RCT conducted by the authors. I have a number of minor comments that could be considered before the article is suitable for publication.

p. 3: suggest specifying what exactly is meant by an immersive VR scenario at this stage in the article (i.e., what sensory substitutions are necessary to facilitate this experience – vision, hearing, touch – and what equipment is absolutely necessary for the user to access the intervention). A more technical definition of immersive VR in the context of this study would also be more informative, offering a greater understanding of what the end-user is experiencing.

p. 3: further description of the specific features (presence/co-presence, immersion) of immersive VR that are being utilized in this intervention would be important here due to the novelty of the technology – particularly in this field. Linked to this, as immersion appears to be a key hypothesised determinant of research question 3, further discussion about immersion as a phenomenon would strengthen the rationale for exploring the use of immersive VR in this context.

p. 8: suggest including any data available on the user testing conducted in December 2020 (researcher notes/observations, reflexive notes, etc.) as it would offer more insight into the processes involved in designing this intervention as suggested in the recommendations offered at the end of this article – further qualitative research into end-users’ experiences and the application of user-centred design principles.

p. 12: if the data is available, it would be useful to know what other immersive VR devices participants who already had the equipment were using. Current immersive VR technologies can differ significantly, affecting key experiences such as presence and immersion.

p. 13: suggest supporting claims of novelty effects and the effects varying levels of immersion have on immersive VR participants’ experiences with past research.

p. 13: typological error – “third” used twice when outlining limitations

--------------------

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Dennis de Ruijter

Reviewer #2: No

Reviewer #3: No

--------------------

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLOS Digit Health. doi: 10.1371/journal.pdig.0000060.r003

Decision Letter 1

Laura M König, Liliana Laranjo

20 Apr 2022

PDIG-D-22-00003R1

A pilot randomised trial of a brief virtual reality scenario in smokers unmotivated to quit: Assessing the feasibility of recruitment

PLOS Digital Health

Dear Dr. Perski,

Thank you for submitting your manuscript to PLOS Digital Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Digital Health's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Based on additional comments submitted by one of the reviewers, I would like to ask the authors to make the following changes:

- Briefly summarize the results presented in the supplementary material in the main text to contextualize the meaning of "remained similar".

- The authors state that the concept of acceptability is debated; this debate should be reflected in the discussion.

- The reviewer highlights that acceptability and susceptibility might be strongly correlated due to the wording of the items. This is a valid concern should be addressed.

Please submit your revised manuscript by Jun 19 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at digitalhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pdig/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

* A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

* A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

* An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Laura M. König

Academic Editor

PLOS Digital Health

Journal Requirements:

1. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article's retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments (if provided):

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: (No Response)

Reviewer #3: All comments have been addressed

--------------------

2. Does this manuscript meet PLOS Digital Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

Reviewer #3: Yes

--------------------

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: No

Reviewer #3: Yes

--------------------

4. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

--------------------

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Digital Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

--------------------

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: I would like to thank the authors for carefully addressing all the feedback received. I do not have any additional remarks. Good luck with the publication process!

Reviewer #2: I would like to thank the authors for taking the time and effort to revise their manuscript. I appreciate the clarifications throughout the manuscript, but still have a few questions or concerns, mainly regarding to the operationalization and validity of measures:

1. I am not fully convinced that the benefit of the dichotomization in aiding the interpretation of results outweighs the concern of loss of information. The concepts measured clearly reflect continuous concepts and a clear rationale for the cutoffs chosen is missing. From my personal viewpoint, the previously planned analyses with regressions (maybe except for intention to change) would yield more informative results.

2. As to the additional analyses in Supplementary File 3, can the authors explain what “remain similar” means? Again, I belief that reporting (descriptive) means intervention vs. control would be more informative than proportions across the likert scale.

3. I am still struggling to grasp as to how the affective beliefs should capture acceptability. One item example is “made me feel distressed”, and if participants report that the disagreed this was coded as acceptable. However, the scenario was expected to raise emotions, so distress might reflect that health consequences were perceived as intended in the scenario (similar to a manipulation check)? This might pose a problem for the measure of acceptability. Can the authors please explain how this should conceptualize non-acceptability? Also, was a mean score of cognitive and affective attitudes calculated? If yes, please explicitly state so.

4. What is the correlation among the variables assessed. As with regard to my second concern, I am wondering if acceptability might correlate/overlap strongly with the measure of susceptibility.

Reviewer #3: (No Response)

--------------------

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: Yes: David Healy

--------------------

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLOS Digit Health. doi: 10.1371/journal.pdig.0000060.r005

Decision Letter 2

Laura M König, Liliana Laranjo

7 May 2022

A pilot randomised trial of a brief virtual reality scenario in smokers unmotivated to quit: Assessing the feasibility of recruitment

PDIG-D-22-00003R2

Dear Dr Perski,

We are pleased to inform you that your manuscript 'A pilot randomised trial of a brief virtual reality scenario in smokers unmotivated to quit: Assessing the feasibility of recruitment' has been provisionally accepted for publication in PLOS Digital Health.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow-up email from a member of our team. 

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact digitalhealth@plos.org.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Digital Health.

Best regards,

Laura M. König

Academic Editor

PLOS Digital Health

***********************************************************

Reviewer Comments (if any, and for reference):

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 CONSORT Checklist. CONSORT checklist of information to include when reporting a pilot or feasibility trial.

    (DOC)

    S1 Data. Behaviour change techniques (BCTs) included in the intervention scenario, coded against a 44-item taxonomy of BCTs used in behavioural smoking cessation interventions [33].

    (XLSX)

    S1 Table. Results from linear regression analyses with the outcome variables (except for intention to stop smoking) operationalised as continuous in addition to the bivariate correlations between the acceptability and perceived susceptibility indicators.

    (DOCX)

    Attachment

    Submitted filename: Responses to reviewer comments 21.03.22.docx

    Attachment

    Submitted filename: Responses to reviewer comments 01.05.22.docx

    Data Availability Statement

    The data underpinning the analyses are openly available via Zenodo: https://doi.org/10.5281/zenodo.5747705. The R code is openly available via GitHub: https://github.com/OlgaPerski/VR_study.


    Articles from PLOS Digital Health are provided here courtesy of PLOS

    RESOURCES